This study tests a new drug, SAR443579, for people with certain blood cancers like Acute Myeloid Leukemia (AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), and others. The study is called "first-in-human" because it's the first time this drug is being tested in humans. It is an open-label study, meaning everyone knows the treatment being given. The study will last about 2.5 years for each participant.
Participants must be at least 1 year old, or 2 years in France, and have specific types of blood cancers that haven't responded to other treatments. Some people cannot participate, like those with other serious health conditions or who are pregnant.
- Study Length: 2.5 years involvement.
- Eligibility: Must have certain blood cancers and no other treatment options.
- Participation: Not allowed if pregnant or have certain health conditions.
Consider if you meet the requirements and are willing to commit to a long study period. Participating could help find new treatments for tough-to-treat blood cancers.